Survival Rate and Prognosis for Vulvar Cancer
Understanding the survival rate and prognosis for vulvar cancer is an important step for patients and their families navigating this diagnosis. This article provides a SEER-based overview of vulvar cancer survival rates by stage, the factors that shape an individual’s outlook, and how treatment affects long-term survival.
Key Takeaways
- Nationally, 69.7% of women given a vulvar cancer diagnosis went on to live at least five years, an all-stage average drawn from SEER’s most recent U.S. registry data; it masks a much steeper drop-off once the disease has spread.
- Per SEER registry data, outcome tracks closely with stage: five-year relative survival sits at 85.5% while the disease is still confined to the vulva, falls to 51.4% after it involves nearby lymph nodes, and drops further to 20.8% once it has spread to organs farther away.
- According to NCI, whether the cancer has spread to the lymph nodes matters more than the size of the primary tumor: reported 5-year survival runs around 90% when the lymph nodes are free of disease, versus roughly 50% to 60% once they are involved.
- Surgery is the primary treatment for most vulvar cancers, often paired with radiation therapy; chemotherapy is generally reserved for locally advanced or recurrent disease.
- These figures come from following large numbers of patients for years afterward; they capture a group-wide pattern, not a forecast for any individual’s case.
Vulvar Cancer Survival Rates Explained
Clinicians typically frame vulvar cancer prognosis around 5-year relative survival: the proportion of patients still living five years post-diagnosis, benchmarked against similarly aged people who never had the disease. It’s a population measure, not a prediction for any individual, and it cannot account for a person’s specific tumor characteristics or overall health.
Vulvar cancer is uncommon, making up about 0.3% of new cancer diagnoses in the United States. Because early detection has such a strong effect on outlook, prompt evaluation of any new vulvar symptom matters; how the disease is typically found is covered on its own page. Data from the SEER (Surveillance, Epidemiology, and End Results) Program at the National Cancer Institute provides the population-based figures used throughout this page.
Vulvar Cancer Survival Rates by Stage
Vulvar cancer stage describes how far the disease has grown and spread at diagnosis. Two staging frameworks exist for vulvar cancer — FIGO’s and one maintained by the American Joint Committee on Cancer — but FIGO is the one used in everyday practice, assigning a stage from I through IV based on tumor extent, local spread, and lymph node involvement. SEER groups these stages into three broader categories for reporting survival: about 58% of vulvar cancers are found while still localized to the vulva, 27% after spreading to nearby lymph nodes or tissue, and 8% after reaching distant sites, with staging unavailable for the rest. The figures below cover U.S. vulvar cancer cases identified from 2016 through 2022, drawn from SEER’s registry.
| SEER Stage | Description | Approximate 5-Year Relative Survival |
|---|---|---|
| Localized | Cancer is confined to the vulva. | 85.5% |
| Regional | Cancer has spread to nearby (inguinal or femoral) lymph nodes or tissue. | 51.4% |
| Distant | Cancer has spread to distant parts of the body. | 20.8% |
| All Stages Combined | Overall survival rate across every stage, including unstaged cases. | 69.7% |
| Data: SEER Program at the National Cancer Institute; U.S. vulvar cancer diagnoses, 2016–2022. | ||
Localized disease carries close to double the survival of regional disease and roughly four times that of distant disease, which is why prompt attention to any unusual vulvar symptom and regular gynecological check-ups remain central to a favorable outlook.
Key Factors Affecting Vulvar Cancer Prognosis
Beyond stage at diagnosis, several other factors are weighed when clinicians estimate an individual patient’s outlook and plan treatment. These factors are considered together rather than in isolation, since a person’s prognosis reflects the combination of tumor biology, extent of disease, and overall health rather than any single measurement.
Because of this interplay, two people diagnosed at the same stage can still have different outcomes. This is part of why a thorough diagnostic workup and an individualized treatment and follow-up plan matter as much as the stage itself.
Disease Stage and Spread
Prognosis depends largely on whether the cancer has spread to the inguinal lymph nodes and whether it has invaded nearby structures such as the urethra, vagina, or anus. According to NCI, nodal status is the strongest determinant of survival: in patients whose disease is surgically treatable and has not spread to the lymph nodes, the overall survival rate is about 90%, compared with roughly 50% to 60% once the lymph nodes are involved.
Distant metastasis — spread to organs away from the vulva — marks the most advanced disease and carries the lowest survival, reinforcing why detecting vulvar cancer before it spreads matters most for long-term outlook.
Tumor Characteristics and Biology
Per NCI, squamous cell carcinoma accounts for the large majority of invasive vulvar cancer cases, over 90% by most estimates, with a handful of other cell types making up the remainder. Unlike many cancers, the size of the primary tumor plays a comparatively minor role in prognosis once lymph node status and local spread are taken into account — it is the pathological status of the lymph nodes, not tumor size, that drives the outlook described above.
Vulvar squamous cell cancers arise through two recognized pathways, one linked to human papillomavirus (HPV) infection and one that is not; the specific type present is identified through pathology after biopsy. The causes and risk factors behind each pathway are covered on their own page, since they don’t change the survival figures described here.
Treatment Outcomes and Long-Term Survival
Surgery remains the primary treatment for most vulvar cancers. Over recent decades, practice has shifted toward less extensive surgery where appropriate: excising the tumor with roughly a 1-centimeter margin of surrounding tissue now more often takes the place of removing the entire vulva, when disease is confined to the vulva or perineum — an approach intended to preserve function while still clearing the cancer. A multidisciplinary team, including gynecologic oncology, radiation oncology, and medical oncology, works together to individualize the plan.
Treatment options for vulvar cancer typically include:
- Surgery: Ranges from wide local excision to radical vulvectomy, depending on tumor size and location. Groin lymph node evaluation is a routine part of surgical staging; sentinel lymph node dissection can identify some patients who can avoid a full groin lymph node dissection and its associated morbidity.
- Radiation Therapy: Used after surgery to address any remaining disease, or as a primary treatment — sometimes combined with chemotherapy — for patients who cannot tolerate radical surgery.
- Chemotherapy: Generally reserved for advanced, recurrent, or metastatic disease, sometimes combined with radiation.
- Targeted Therapy and Immunotherapy: Considered for advanced or recurrent cases where standard approaches have not controlled the disease.
Because invasive and preinvasive vulvar disease can involve HPV effects across a wide area of vulvar skin, patients are monitored regularly after treatment for any sign of recurrence. Adherence to this follow-up schedule supports early detection of recurrence and long-term health.
Frequently Asked Questions
What is the typical recovery time after vulvar cancer treatment?
Recovery depends on the extent of treatment: initial healing after surgery often takes several weeks, with fuller recovery over a few months, while radiation therapy can cause fatigue and skin irritation that may persist for weeks afterward. Because timelines vary with overall health and treatment intensity, patients should discuss specific expectations with their care team.
Can vulvar cancer recur after successful treatment?
Yes. Recurrence risk depends on factors such as the original stage, lymph node involvement, and the treatment received. Regular follow-up exams help catch any recurrence early, when it is generally most treatable.
Are there lifestyle changes that can improve vulvar cancer prognosis?
Lifestyle changes cannot cure vulvar cancer, but a balanced diet, regular activity as tolerated, avoiding smoking, and limiting alcohol can support overall well-being during and after treatment. These measures complement medical care rather than replace it.
Sources
